Non-Invasive methods to Determine Vulnerable Plaque Burden in Subjects
AssigneeSingulex, Inc.
InventorsJohn Allan Todd, Quynh Anh Thuc Lu, Jeffrey David Greenberg
Life of this patent
Estimating the term…
Abstract
Methods, kits, and systems for determining vulnerable plaque burden in a subject. The methods involve measuring an amount of at least one biomarker in a blood sample from the subject, wherein the at least one biomarker is selected from the group consisting of vascular endothelial growth factor-A (VEGF), cardiac troponin I (cTnI), and matrix metalloproteinase-9 (MMP-9). The concentration of these biomarkers in a sample from the subject are used to determine vulnerable plaque burden in the subject.
Claims12
A method for determining vulnerable plaque burden in a subject comprising:
- measuring an amount of at least one biomarker in a blood, serum or plasma sample from the subject, wherein the at least one biomarker is selected from the group consisting of vascular endothelial growth factor-A (VEGF), cardiac troponin I (cTnI), and matrix metalloproteinase-9 (MMP-9);
- comparing the amount of the at least one biomarker in the biological sample from the subject to a threshold concentration representing the concentration of the at least one biomarker in a population of normal healthy control subjects, and
- determining vulnerable plaque burden in the subject when the concentration of at least one biomarker in the sample is greater than the threshold concentration.
A method for determining vulnerable plaque burden in a subject comprising:
- measuring the concentration of one or more biomarkers selected from the group consisting of VEGF, cTnI and MMP-9 in a blood, serum or plasma sample from a patient,
- standardizing the biomarker concentrations in the sample to threshold concentrations for the biomarkers in a population of normal healthy controls to create a ratio of the concentrations in the sample and the threshold concentrations,
- wherein the ratios represent the vulnerable plaque burden in the subject.
A method for determining vulnerable plaque burden in a subject comprising:
- measuring an amount of at least two biomarkers selected from VEGF, cTnI or MMP-9 in a blood, serum or plasma sample from a patient,
- standardizing the biomarker concentrations in the sample to threshold concentrations of the biomarkers in a population of normal healthy controls to create ratios of the concentrations in the test sample and the threshold concentrations,
- adding the ratios to create a score representing vulnerable plaque burden in the subject.
The method of claim 11, wherein the measuring is conducted with a single molecule counting assay.
Dependencies are inferred from the claim text.